Women in CRISPR/Cas9 genome editing research - List Version 3
First Name
Last NameOrganisationLocationCountryPositionWebsite
Twitter Handle
Field of Research
Research Interest
BrittAdamsonPrinceton UniversityPrinceton, NJUSAAssistant Professor
Technology Development - high througput screening - repair pathway
Genome editing technologies that target programmable sequence changes to specific genomic loci have substantial potential for therapeutic applications. However, realizing the promise of these approaches will require improving their to-date limited specificity. We have recently pioneered methods to systematically investigate how synthetic mechanisms of genome editing, including CRISPR-based single-strand template repair and DNA base editing, interact with endogenous DNA repair networks. One goal of this work is to identify parameters that can be tuned to achieve optimal in vitro and in vivo editing outcomes.
FrancoiseBaylisDalhousie UniversityHalifaxCanadaProfessor
Françoise Baylis is an internationally renowned bioethics expert whose innovative work, at the intersection of policy and practice, has stretched the very boundaries of the field. Her ethics research focuses primarily on women’s reproductive health and genetic technologies. Her work aims to move the limits of mainstream bioethics by developing more effective ways to understand and tackle public policy challenges. Baylis believes bioethicists need to exercise their moral imagination and find creative ways to make the powerful care.
DivakiBhayaStanford UniveristyStanford, CAUSAProfessor
Evolution and Ecology - microbial diversity - Plant Biology
Research in my lab is driven by an interest in understanding how photosynthetic microorganisms perceive and evolve in response to environmental stressors, such as light, nutrients and viral attack.We work both with model organisms and with cyanobacteria in naturally occurring communities. Recently,we have started to develop synthetic biology-inspired approaches to use in cyanobacteria.
JillBanfieldUniversity of California BerkeleyBerkeley, CAUSAProfessorhttp://nanogeoscience.berkeley.eduEvolution and Ecology - microbial diversity
The study system for this project is an aquifer adjacent to the Colorado River in Rifle, Colorado, USA.Research addresses knowledge gaps related to the roles of subsurface microbial communities in biogeochemical cycling. Given the link between the carbon cycle and global climate change, a particular interest in this work is the impact of microorganisms on carbon compounds buried in the terrestrial subsurface, both through respiration and carbon fixation.
CassandraBarrettArizona State University ASUTempe, AZUSAPhD student
Synthetic Biology - Epigenetics - Technology development
We are using synthetic chromatin proteins to build a permanently re-opened state at epigenetically silenced genes. We aim to achieve unprecedented reliability for the expression of synthetic genes and improvement of CRISPR/Cas9-mediated gene editing in mammalian cells
Commonwealth Scientific and Industrial Research Organisation (CSIRO)
SydneyAustraliaHead of laboratory biology - Technology development
Dr. Denis Bauer is the team leader of the transformational bioinformatics team in CSIRO’s ehealth program. Her expertise is in high throughput genomic data analysis, computational genome engineering, as well as Spark/Hadoop and high-performance compute system.
PilarBlancafortHarry Perkins Institute for Medical ResearchPerthAustraliaAssociate Professor biology - Technology Development
The Blancafort laboratory focuses on the development of novel approaches to target cancers that are currently refractory to treatment and associated to poor outcome, such as triple negative breast cancers and ovarian cancers. At present, there are no targeted approaches to combat these tumors with chemotherapy and radiation the only treatment options. The laboratory generates novel functionalised molecules able to specifically target these tumors with minimal toxicity to normal cells. Our emphasis is in advanced stage metastatic tumors, which quasi invariably develop resistance. Ultimately we wish to revert the behavior of metastatic cells by sensitizing these treatment resistant tumors to chemotherapy regimes.
IrinaBorodinaDTU Technical Univesity of DenmarkLyngbyDenmarkSenior Scientist Biology/Chemical Biology using Yeast
We focus on metabolic engineering of yeast cell factories for biosustainable production of chemicals from renewable feedstocks. Our projects include both commodity chemicals, such as 3-hydroxypropionic acid for bioacrylics, and fine chemicals.We develop genetic engineering tools, which facilitate iterative cycles of strain development, and work on general methodology for accelerated rational strain design, based on systems biology-level data (fluxome, transcriptome, metabolome, etc) and modeling.
KatharinaBoroviakWellcome Sanger InstituteCambridgeUKStaff Scientist
Developmental Biology - Stem cells - Technology Development
The Bradley laboratory is a multi-disciplinary environment with a number of parallel research themes. One of our core disciplines is the development and use of genetic technologies which we primarily apply to the mouse genome, although we also embrace studies in other mammalian genomes.
AlexaBurgerUniversity of ZurichZurichSwitzerlandSenior postdoctoral fellow - Technology development
CRISPR application in Zebrafish (ribonucleic complex and increase mutation efficiency)
AltaCharoUniversity of Wisconsin at MadisonMadison, WIUSAProfessor
Professor Charo has authored or contributed to over 100 articles, book chapters and government reports on law and policy related to environmental protection, reproductive health, new reproductive technologies, medical genetics, stem cell research, science funding, and research ethics.
EmmanuelleCharpentierMax Plank InstituteBerlinGermanyProfessor interaction
Our research relates to the field of Molecular Infection Biology. We are overall interested in understanding the molecular mechanisms governing physiology-, virulence- and infection-associated processes in Gram-positive bacterial pathogens. We use a combination of genetic, genomic, molecular, biochemical, physiological and cell infection approaches to study mechanisms of gene expression at the transcriptional and post-transcriptional level in horizontal gene transfer, adaptation to stress, physiology or virulence. In particular, we do research on CRISPR, the adaptive immune system that protects bacteria against invading genetic elements; the small regulatory RNAs that interfere with bacterial pathogenicity; protein quality-control that regulates bacterial adaptation, physiology and virulence; and the mechanisms of bacterial recognition by immune cells.
Janice ChenMammoth BiosciencesBerkeley, CAUSASenior Scientist biology - diseases detection
Mammoth’s vision is to provide a CRISPR-based platform on which an infinite number of tests can be built by both ourselves and our partners - democratizing access to an endless variety of tests for bio sensing in healthcare, as well as across industries such as agriculture, manufacturing, forensics, and more.
SylviaComporesiKings College LondonLondonUKLecturer
I am a bioethicist with an interdisciplinary background in medical biotechnologies, ethics and philosophy. I am a tenured Lecturer (the UK equivalent to Assistant Professor) in Bioethics & Society in the Department of Global Health & Social Medicine (formerly, Social Science, Health & Medicine) at King’s College London, where I direct the Master’s in Bioethics & Society.
ElenaContiMax Plank InstituteMartinsriedGermanyGroup leader and Director Biology - RNA biology
Our group has a long-standing interest in RNA metabolism, with a particular focus on the molecular mechanisms of eukaryotic RNA transport and degradation.
KimberleyCooperUniversity of California - San DiegoSan Diego, CAUSAAssistant Professor Biology - Gene Drives in mouse
Most of the genes required for limb development are needed by both the arms and legs. However many animals have very different fore and hindlimbs, and 95% of human congenital limb defects specifically affect the arms or legs but not both. How are shared genes deployed differently in the two pairs of limbs?
CeciliaCotta RamusinoEditas MedicineCambridge, MAUSASenior Scientisthttp://www.editasmedicine.comTherapy - Technology development
Exploring CRISPR/Cas9 gene editing technology for therapeutics purposes
AnnaCraterNational Institute of HealthRockville, MDUSAPostdoctoral fellow@DrAnnaCPMolecular Biology of Malaria
Genetic modifications and nutrient uptake of the malaria parasite
ReneeDaerArizona State University ASUTempe, AZUSAPostdoctoral fellow - Technology Development
Investigating the impact of chromatin dynamics on Cas9-mediated genome editing in mammalian cells
JoanaDe Campos VidigalMemorial Sloan KetteringNew York, NYUSAPostdoctoral fellow biology - Non coding RNA
One of the most exciting discoveries of the last two decades has been the identification of a large number of non-coding RNAs and the realization that they play essential roles in mammalian development and in diseases. Their study and the characterization of their contribution to the pathogenesis of human cancer is the central focus of our group.
RaffaellaDi MiccoSan Raffaele Telethon Institute for Gene therapySan RaffaeleItalyGroup leader
@DiMiccoLabStem cells - Aging, differentiation and Cancer
Group research activity is interested in dissecting the mechanisms that regulate cellular senescence during aging, differentiation and cancer. Gene transcription, chromatin conformation and DNA damage orchestrate the tightly controlled program of cellular senescence. However, very little is known on how the identity of senescence cells is established and how it contributes to fundamental biological processes such as aging, cellular differentiation and cancer. By combining cell and molecular biology approaches, together with next generation sequencing and clinically relevant human samples, the unit is elucidating the functional role of senescence-associated pathways and regulators in the hematopoietic stem cell compartment (HSPCs)
JenniferDoudnaUniversity of California BerkeleyBerkeley, CAUSAProfessor biology - Adaptive immunity
Exploring molecular mechanisms of RNA-mediated gene regulation
MasakiEndoNational Agriculture and Food Research OrganizationTsukubaJapanSenior Researcher
Plant biology - Gene targeting
Genome editing technology is expected to become a systematic strategy in modifying target genes. In addition to improving the accuracy and efficiency of genome editing technology, this unit aims to develop technology for modifying useful genes based on the genomic information and integrating useful traits by modifying multiple genes, and the devolopment of new breeding materials.
YanfangFuBeam TherapeuthicsCambridge, MAUSASenior Research Scientist
Technology development - Human therapeuthics - Base editing
The human genome is made up of billions of nucleobases, or “bases,” represented by the letters The human genome is made up of billions of nucleobases, or “bases,” represented by the letters A, G, T, and C. Beam’s base editing technology can precisely target and make specific edits to a single base in DNA or RNA, without cutting or disrupting the gene. Base editors have the potential to repair disease-causing point mutations, write in protective genetic variations, or modulate the expression or function of disease-causing genes. Beam is committed to developing base editors as a new class of precision genetic medicines that can treat or cure diseases affecting patients’ lives.A, G, T, and C. Beam’s base editing technology can precisely target and make specific edits to a single base in DNA or RNA, without cutting or disrupting the gene. Base editors have the potential to repair disease-causing point mutations, write in protective genetic variations, or modulate the expression or function of disease-causing genes. Beam is committed to developing base editors as a new class of precision genetic medicines that can treat or cure diseases affecting patients’ lives.
CaixiaGaoChinese Academy of ScienceBeijingChinaProfessor biology (Wheat) - Technology development
The main research goal of our laboratory is to develop high-throughput transgene technologies for common wheat (Triticumaestivum L.) and maize (Zea mays) and other major crops to satisfy the needs of crop improvement and gene discovery.
NicoleGaudelliBeam TherapeuthicsCambridge, MAUSASenior Scientist and Program Leader
Technology development - Human therapeuthics - Base editing
The human genome is made up of billions of nucleobases, or “bases,” represented by the letters The human genome is made up of billions of nucleobases, or “bases,” represented by the letters A, G, T, and C. Beam’s base editing technology can precisely target and make specific edits to a single base in DNA or RNA, without cutting or disrupting the gene. Base editors have the potential to repair disease-causing point mutations, write in protective genetic variations, or modulate the expression or function of disease-causing genes. Beam is committed to developing base editors as a new class of precision genetic medicines that can treat or cure diseases affecting patients’ lives.A, G, T, and C. Beam’s base editing technology can precisely target and make specific edits to a single base in DNA or RNA, without cutting or disrupting the gene. Base editors have the potential to repair disease-causing point mutations, write in protective genetic variations, or modulate the expression or function of disease-causing genes. Beam is committed to developing base editors as a new class of precision genetic medicines that can treat or cure diseases affecting patients’ lives.
MaryGearingFoundation MedicineBoston MAUSAScientist communication
I am a molecular biologist and science communicator. In my current role at Foundation Medicine, I help create reports detailing the genomic profile of patient tumors and relevant therapeutic options.
CarineGiovanangeliMuseum National d'Histoire NaturelleParisFranceDirector of Researchénomiques+et+réponses+cellulairesDNA repair mechanisms - Technology development
Nowadays, we are mainly focusing on novel artificial DNA binding domains, the TALE repeats (transcription-activator like effector) and CRISPR/Cas9 system. We use the CRISPR/Cas or TALE as nucleases (TALEN) to study DNA repair in mammalian cells as well as DNA probes to study genome dynamics (see Repeated DNA sequences and chromatin).
NataliaGomez-OspinaStanford UniveristyStanford, CAUSAClinical Instructor cell biology - Clinical therapy
Dr. Gomez-Ospina was born and raised in Medellin, Colombia. She began her undergraduate studies in petroleum engineering at the Universidad Nacional de Colombia before moving to Colorado. She double majored at the University of Colorado Boulder, completing her bachelor’s degree in Molecular Cellular and Developmental Biology as well as Biochemistry. She graduated summa cum laude and wrote an honors thesis entitled “Role of the quiescent center in the regeneration of the root cap in Zea Mays.” She then completed her combined MD, PhD at Stanford Medical School, where her PhD work focused on understanding the novel functions of voltage-gated calcium channels. Her PhD thesis, “The calcium channel CACNA1C gene: multiple proteins, diverse functions,” was published in Cell. After completion of her dual degrees, she did her preliminary year in internal medicine at Santa Barbara Cottage hospital before starting residency in Dermatology at Johns Hopkins Hospital. She completed residency in Medical Genetics at Stanford Hospital and clinics. She is currently doing her post-doctoral research with Dr. Matthew Porteus in Pediatric Stem Cell transplantation, where she is developing a genome editing strategy in stem cells as a curative therapy for metabolic diseases. In addition to her research, Dr. Gomez-Ospina is a clinical instructor in Medical Genetics. For her clinical practice she sees patients with suspected genetic disorders, and is also in charge of the enzyme replacement service for lysosomal storage disorders at Lucile Packard Children’s hospital. She has been the lead author in research studies in The New England Journal of Medicine, Cell, Nature Communications, and American Journal of Medical Genetics.
DinaGrohmannRegensburg UniversityRegensburgGermanyProfessor of Microbiology
RNA Biology - Prokaryote Argonautes - Single molecule analysis
n eukaryotic organisms, Argonaute is the functional core of the RNA-silencing machinery critically involved in the regulation of gene expression. Despite the mechanistic and structural similarities between archaeal, bacterial and eukaryotic Argonaute proteins, the biological function of bacterial and archaeal Argonautes is only poorly understood
CarolGrossUniversity of California - San Francisco UCSF
San Francisco, CA
USAPrincipal Investigator genomics on E.coli - synthetic Biology
The Carol Gross Lab takes genetic, biochemical, and systems approaches to study regulatory mechanisms of E. coli stress responses, protein interactions in the bacterial transcription apparatus, and genome-wide control of gene expression.
HannahGrunwald (Gee)University of California - San Diego UCSDSan Diego, CAUSAPhD student Biology - Gene Drives in mouse
I am working on using mice to model the evolutionary changes in gene regulation that led to the loss of toes, but not fingers, in the lesser Egyptian jerboa.
Jodi HalpernUniversity of Cafifornia - Berkeley Berkeley, CAUSAProfessor
Her work brings together psychiatry, philosophy, affective forecasting and decision neuroscience to study how people imagine and change their own – and each other’s – future possibilities.
AsmaHatoum-AslanThe University of AlabamaTuscaloosa, ALUSAAssistant Professor interaction
Bacterial infectious diseases are a major cause of mortality worldwide. The rise in antibiotic resistant infections, coupled with the sharp decline in the discovery of new and clinically useful classes of antibiotics, underscores an urgent need for alternative strategies to combat bacterial infections. Small noncoding RNA pathways have recently been recognized as important regulators of bacterial pathogenesis, and the challenge lies in gaining a detailed understanding of these processes. My research uses the tools of biochemistry and molecular genetics to unravel the mechanisms of small RNA-mediated pathways and enable the development of novel anti-microbial therapeutics.
RachelHaurwitzCaribou BiosciencesBerkeley, CAUSAPresident and Chief Executive officer - Technology development
Rachel is a co-founder of Caribou Biosciences and has been President and CEO since its inception. She has a research background in CRISPR-Cas biology, and is also a co-founder of Intellia Therapeutics. In 2014, she was named by Forbes Magazine to the "30 Under 30" list in Science and Healthcare, and in 2016, Fortune Magazine named her to the "40 Under 40" list of the most influential young people in business. Rachel is an inventor on several patents and patent applications covering multiple CRISPR-derived technologies, and she has co-authored scientific papers in high impact journals characterizing CRISPR-Cas systems. Rachel earned an A.B. in Biological Sciences from Harvard College, and received a Ph.D. in Molecular and Cell Biology from the University of California, Berkeley.
KarmellaHaynesArizona State University ASUTempe, AZUSAAssistant Professor
Synthetic Biology - Epigenetics - Technology development
We are using synthetic chromatin proteins to build a permanently re-opened state at epigenetically silenced genes. We aim to achieve unprecedented reliability for the expression of synthetic genes and improvement of CRISPR/Cas9-mediated gene editing in mammalian cells
LinHeUniversity of California - BerkeleyBerkeley, CAUSAAssociate Professor
Mouse editing - Technology development - non coding genome
​CRISPR-mediated mouse genome editing is typically accomplished by microinjection of Cas9 DNA/RNA and sgRNA into zygotes to achieve editing in one step. We developed a simple and economic electroporation-based strategy, designated as CRISPR RNP Electroporation of Zygotes (CRISPR-EZ), to deliver Cas9/sgRNA ribonucleoproteins (RNPs) into mouse zygotes with 100% efficiency. CRISPR-EZ enables highly efficient and high-throughput genome editing in vivo, with a significant improvement in embryo viability compared with microinjection-based technology.
Kelly HillsRogue BioethicsUSAPrincipal Scientist
A software test engineer before she returned to school for bioethics, Kelly utilizes her expertise in both fields to consult on emerging ethical issues in novel technologies, including self-driving vehicles and other forms of impending robotic doom, synthetic biology, conflicts of interest, and biosecurity.
MeganHochstrasserInnovative Genomics InstituteBerkeley, CAUSAScience Communication manager - Science communication
Megan has a B.A. in Biology from Brown University and received her Ph.D. from Jennifer Doudna's lab at UC Berkeley in 2016, where she studied mechanisms of CRISPR immunity in bacteria. She joined the IGI in September 2016 to handle scientific communications, hoping to bridge the gap between researchers and the public.
SaraHowdenMurdoch Children Research InstituteMelbourneAustraliaSenior Research Fellow cell biology - Technology development
Around 10-20% of kidney disease is inherited. In children with kidney disease, this is closer to 50% although in many instances, the disease-causing mutation is unknown, therefore limiting treatment options. In our research group, we investigate the genes required for normal kidney development and what happens as a result of genetic or environmental damage during development. This knowledge is used to try to recreate kidney stem cells. We have developed methods for generating mini-kidneys from human stem cells that represent models of the human organ. We hope to use these mini-kidneys to screen drugs for kidney toxicity, as models with which to understand kidney disease, to generate cells for the treatment of kidney disease and eventually to bioengineer replacement organs.
NinaHoyland-kroghsboPrinceton UniversityPrinceton, NJUSAPostdoctoral fellow interaction
Research Interest: The global threat of multi-drug resistant bacteria urgently demands alternatives to conventional antibiotics. Two promising alternatives to traditional antibiotics are bacteriophage (phage) therapy and inhibitors of bacterial cell-cell communication, known as quorum sensing (QS). Bacteria in high cell density maximally engage in QS. These cells are particularly vulnerable to phage infections, which could rapidly spread and kill the population. QS-control of antiphage activities would enable bacteria to specifically activate defenses when they are at the highest risk of infection. I am investigating to what extent bacteria use QS to regulate their antiphage defenses. Whereas QS-inhibitory compounds are generally studied for their capacity to inhibit bacterial virulence, I will study whether they additionally have the ability to increase the vulnerability of pathogenic bacteria to phages.
DanweiHuangfuMemorial Sloan KetteringNew York, NYUSAHead of laboratory cell biology - Technology development
The ability to program naïve cells or to reprogram differentiated cells into particular fates will open the door to the discovery of novel therapeutics for diseases such as diabetes. The goal of my lab is to understand the fundamental principles that govern the identity of a cell, and to use these principles to manipulate cell fates for regenerative medicine. In pursuit of this goal, we employ a variety of approaches including cellular programming and reprogramming through gene transduction, directed differentiation of embryonic stem (ES) cells, chemical screening, mouse genetics, adult tissue injury and regeneration, and tissue/cell transplantation.
MariaJasinMemorial Sloan KetteringNew York, NYUSAHead of laboratory repair mechanisms - DSB
Human chromosomes are constantly assaulted by challenges to their integrity as a result of either environmental agents that damage DNA or from normal DNA metabolism. The failure to repair damaged DNA faithfully is ultimately responsible for many human diseases, especially cancer. This laboratory focuses on the repair of 1 particular lesion in DNA, the double-strand break (DSB). DSBs arise from agents, such as ionizing radiation, and can also occur spontaneously during DNA replication. Our emphasis is on repair of DSBs by homologous recombination, with a particular interest in the role of homologous recombination in maintaining genetic stability. Understanding the repair of DSBs is not only important for basic science and health concerns, but also impacts on molecular genetic manipulations of mammalian genomes
JosephinJohnstonThe Hasting CentreGarrison, NYUSADirector of Research
Josephine Johnston is an expert on the ethical, legal, and policy implications of biomedical technologies, particularly as used in human reproduction, psychiatry, genetics, and neuroscience.
HeleneJousset-SabrouxThe Walter and Eliza Hall Institute for Medical ResearchMelbourneAustraliaHead of laboratoryélène-jousset-sabroux
High Throughput Screening - Technology Development
The screening laboratory offers a wide range of expertise gained from both industrial and academic backgrounds, resulting in a professional ability to develop high capacity cellular or biochemical assays. We offer liquid handling robotics, plate readers and computing programs to increase the scale and speed of assays, and leverage automation to quickly assess the activity of a large number of compounds.
ShaheenKabirInnovative Genomics InstituteBerkeley, CAUSAPostdoctoral fellow Throughput Screening using CRISPR for Cancer
Shaheen Kabir received her PhD in the Biomedical Sciences from The Rockefeller University in New York, in June 2015. She performed her graduate research in the laboratory of Titia de Lange, focusing on understanding mechanisms of DNA repair using telomeres in mammalian cells as a model system. Shaheen joined the IGI staff as an IGI-AZ Postdoctoral Fellow in July 2015, and is currently using CRISPR-Cas9 mediated genome engineering and screening to study various cancers
JoanneKamensAddgeneCambridge, MAUSAExecutive Director Science - Resources on CRISPR - Repository
Addgene is a global, nonprofit repository that was created to help scientists share plasmids. Plasmids are DNA-based research reagents commonly used in the life sciences. When scientists publish research papers, they deposit their associated plasmids at Addgene. Then, when other scientists read the publication, they have easy access to the plasmids needed to conduct future experiments
Bartha MariaKnoppersMcGill UniversityMontrealCanadaDirector of the Centre of Genomics and Policy
Currently, the CGP’s research covers six areas of genomics and policy: stem cell research and therapies, pediatrics, privacy, cancer, intellectual property, and biobanks (population genetics). These domains are approached using three guiding foundations: internationalization, policy development and knowledge transfer
SilvannaKonermannThe Salk InstituteBerkeley, CAUSAPostdoctoral fellow
Genome engineering - manipulation of gene expression
Silvana is a neuroscientist and bioengineer. She received her B.S. in Biology from ETH Zürich and Ph.D. from MIT in Neuroscience, where she was a Hubert Schömaker Fellow. Her graduate work with Feng Zhang focused on developing new methods for manipulating brain gene expression using light and genome-scale transcriptional activation, for which she was awarded the 2015 Harold Weintraub Graduate Student Award. She was a Catharina Foundation Fellow, a winner of the 2017 Salk Women & Science Special Award, and currently an HHMI Hannah Gray Fellow.
AlexisKomorUniversity of California San Diego UCSDSan Diego, CAUSAAssistant Professor
DNA damage and repair; Genome editing; Chemical biology of aging
Aging is a multifaceted process that is believed to be initiated by damage to various cellular macromolecules such as DNA, proteins, and lipids. However, mounting evident supports the theory that damage to DNA plays a more prominent role in aging than other macromolecules. In fact, most documented progeroid syndromes (genetic diseases with phenotypes of accelerated aging) are caused by mutations in DNA repair enzymes. The Komor lab will apply chemical biology approaches to reveal molecular relationships between DNA damage and aging. We will strive to elucidate the underlying mechanisms that connect specific DNA lesions to cellular death and senescence, the major contributors of organismal aging.
MarkitaLandryUniversity of California BerkeleyBerkeley, CAUSAAssistant Professor
Nanoparticle delivery of CRISPR reagents - Gene therapy
Life takes on unique characteristics at the nano-scale. We are accustomed to making observations and predictions for the behavior of living systems on a scale that is intuitive for the time and size scales of our day-to-day lives. For centuries, scientific advancements have been on a size-scale that is familiar to us: distances in meters, times in seconds, masses in kilograms, and volumes in liters. However, the building blocks of life: proteins, nucleic acids, cells, all live at a very different scale. When we zoom into life down to the molecular level, the scales used to describe distances, times, masses, and volumes shrink to a level that is not intuitive to one accustomed to living life at the macro-scale. Our lab focuses on understanding and exploiting nanomaterials to access information about biological systems stored at the nano-scale.
TamsinLannaganUniversity of AdelaideAdelaideAustraliaSenior postdoctoral fellow biology - Technology Development
My role within the group is to develop and assess novel mouse models of colorectal cancer, using colonoscopy techniques that are very similar to patient surveillance in humans. In addition, I am developing an in vitro method of growing mouse and human stem cells from the colon with their associated connective tissue. This will allow us to further investigate these support cells in normal growth and cancer. Both systems will be directly therapeutically relevant, allowing us to assess preclinical targeting of molecular pathways relevant to colorectal cancer.
HongLiFlorida State UniversityTallahassee, FLUSAProfessor Biology - RNA biology
A diverse range of RNA:protein, RNA:RNA and protein:protein interactions occur at the level of transcription and translation as well as post-transcriptional modifications. RNA:protein interactions are particularly interesting not only because they play important functional roles in assembly and biological processes, but also because the rules of their interactions are still poorly understood owing to the scarce structural data. Unlike DNA molecules, RNA can fold into a range of structures for interacting with proteins and small molecules. We hope, by providing exceptionally detailed images of the molecular events along the assembly and functional pathways, to unveil the underlying basis for assembly and functions involving RNA and partner proteins.
JenniferListgartenMicrosoft ResearchCambridge, MAUSASenior Researcherhttp://www.jennifer.listgarten.comComputational biology - Technology development
My area of expertise is in machine learning and applied statistics for computational biology. I'm interested in both methods development as well as application of methods to enable new insight into basic biology and medicine.
ShirleyLiuDana Farber Cancer Institute - HarvardCambridge, MAUSAHead of laboratoryhttp://liulab.dfci.harvard.eduComputational biology - Technology development
We are developing the computational methods for the design (SSC), analysis (MAGeCK), hit prioritization (NEST), and visualization (VISPR) of genome-wide CRISPR screens. We are also using this technology to identify key genes in breast and prostate tumor progression and drug resistance. We also develop CRISPR screen platforms to understand the functions of enhancers and long-noncoding RNAs, and identify synthetic lethal gene pairs in cancer that leads to optimized cancer precision medicine.
MorganMaederEditas MedicineCambridge, MAUSASenior Scientist gene therapy
Dr Morgan Maeder is a Research Scientist at Editas Medicine, Inc. She has extensive experience with engineering targeted nucleases, including ZFNs, TALENs and the CRISPR/Cas system, and applying them in human cells for genetic and epigenetic engineering
KiraMakarovaNCBI, NIHBethesda, MDUSASenior Scientist
Computational Biology - Comparative Genomics - Evolution
We are interested in understanding the evolution of life. To obtain glimpses of such understanding, we employ existing and new methods of computational biology to perform research in several major areas.
AnitaMarchfelderUlm UniversityUlmGermanyHead of laboratory interaction
All prokaryotic cells have to fend off foreign genetic elements like for instance viruses. To do that they have developed several different defence strategies. The recently discovered new defence strategy is the so called prokaryotic immune system also called CRISPR/Cas (CRISPR: clustered regularly interspaced short palindromic repeats, Cas: CRISPR-associated). It is adaptive, since cells can become immune against new invaders and it is heritable, since the information about the invader is stored in the genome. The CRISPR/Cas system consists of clusters of repetitive chromosomal DNA in which short palindromic DNA repeats are separated by spacers, the latter being sequences derived from the invader. In addition, a set of proteins, the Cas proteins, is involved in this defence reaction. We are investigating the CRISPR/Cas system in the halophilic archaeon Haloferax volcanii. Haloferax encodes a type I-B CRISPR/Cas system with eight Cas proteins and three CRISPR RNAs.
KarenMaxwellUniversity of TorontoTorontoCanadaAssistant Professor interaction
The Maxwell lab studies the phages that infect and kill the human bacterial pathogens Escherichia coli, Pseudomonas aeruginosa and Staphylococcus aureus. Infections caused by these bacteria create a significant disease burden, and the increasing incidence of antibiotic resistant infections caused by these pathogens is one of our most serious health threats.
Barbara JMeyerUniversity of California BerkeleyBerkeley, CAUSAHead of laboratory - Technology development
Targeted Genome-editing Across Highly Diverged Nematode Species. Thwarted by the lack of reverse genetic approaches to enable cross-species comparisons of gene function, we established robust strategies for targeted genome editing across nematode species diverged by 300 MYR. In our initial work, a collaboration with Sangamo BioSciences, we used engineered nucleases containing fusions between the DNA cleavage domain of the enzyme FokI and a custom-designed DNA binding domain: either zinc-finger motifs for zinc-finger nucleases or transcription activator-like effector domains for TALE nucleases (TALENs). In those experiments, we allowed the DNA double-strand breaks to be repaired imprecisely by non-homologous end joining (NHEJ) to create mutations in precise locations.
ShondraMillerSt Jude Children's Research Hospital Memphis, TNUSADirector of Research cell biology - Technology development
The Genome Engineering and IPSC Center (GEiC) was formed by the consolidation of two pre-existing cores, the Genome Engineering Center and the Induced Pluripotent Stem cell (iPSC) core, both established by the Department of Genetics in the past few years. These two Centers were established to facilitate functional genomic studies through the use of patient-derived iPSCs and the generation of modified cells and organisms using genome editing technologies.
Catherine MillsMonash UniversityClaytonAustraliaAssociate Professor
Catherine Mills is an Associate Professor in the Monash Bioethics Centre and current recipient of an Australian Research Council Future Fellowship. Her disciplinary background is philosophy, and her research addresses ethical issues in human reproduction, especially from the perspective of feminist moral theory. She also has expertise in aspects of Continental philosophy, particularly the work of Michel Foucault, and debates on biopolitics.
HiromiMiuraTokai University School of MedicineKanagawaJapanAssistant Professor - Technology development
DeniseMonackStanford UniveristyStanford, CAUSAPrincipal Investigator
Immunology - Bacterial infection - high throughput screening
The primary focus of our research is to understand the genetic and molecular mechanisms of intracellular bacterial pathogenesis. We are particularly intrigued by host-adapted pathogens that have evolved to persist within hosts for long periods of time.
MaryMullinsUniversity of PennsylvaniaPhiladelphia, PAUSAProfessor
Stem cell biology - Technology development in zebrafish
We are studying the molecular mechanisms by which a BMP (Bone Morphogenetic Protein) signal transduction pathway establishes different aspects of the vertebrate body plan. Various zebrafish mutants of BMP pathway components, as well as antisense knockdown approaches are used to dissect the molecular mechanisms by which this pathway establishes different cell types. We are studying the formation, function, and temporal regulation of a BMP activity gradient, which is implicated in specification of diverse cell types along the dorsal-ventral axis. We have shown that this gradient is essential in neural crest specification and is linked to dorsal-ventral patterning of neural tissue. Moreover, a subset of our defined components also function in post-embryonic heart development. Misregulation of BMP signaling leads to a debilitating disease in humans called FOP. We are currently trying to establish a model for FOP in the zebrafish.
KathyNiakanThe Francis Crick InstituteLondonUKHead of laboratory cell biology - Technology development
The allocation of cells to a specific lineage is regulated by the activities of key signalling pathways and developmentally regulated transcription factors. The focus of our research is to understand the influence of signalling and transcription factors on differentiation during early human development.
LaurylNutterUniversity of Toronto - Sick KidsTorontoCanadaAssiociate Director Transgenesis - Technology Development
The Centre for Phenogenomics (TCP, formerly "Toronto Centre for Phenogenomics") is owned and operated by Mount Sinai Hospital and The Hospital for Sick Children as a centralized, state-of-the-art national research facility. Open since 2007, TCP provides animal holding, model production, clinical phenotyping, infection and inflammation, imaging, pathology, and cryopreservation and recovery services to users locally, across Canada and around the world.
KateO'Connor-GilesUniversity Wisconson MadisonMadison, WIUSAHead of laboratoryhttp://oconnorgiles.molbio.wisc.eduDrosophila -Technology development
We are also developing genetic technologies for identifying and gaining genetic control of neuronal subtypes to determine their characterize their roles in neural circuits. Working with the laboratories of Jill Wildonger and Melissa Harrison, we recently adapted the CRISPR/Cas9 system for use in Drosophila. CRISPR is a novel technique that is revolutionizing genome engineering. Developed from bacteria where the CRISPR/Cas9 system functions in acquired immunity, CRISPR technology enables highly efficient and specific editing of targeted genomic sequences – opening the door to routine genome engineering. The many applications of CRISPR technology include modifying the genomes of model organisms to probe gene function, conferring disease resistance to agricultural organisms, and correcting disease-causing mutations in humans. We are capitalizing on this advance to develop novel genome engineering approaches that overcome current technological limitations to understanding neural circuits. Visit our flyCRISPR and flyCRISPR Optimal Target Finder sites for more details on our genome engineering work.
Helen O'NeillUniversity College London LondonUKLecturer in reproductive health in embryo - reproductive biology
KeliPalmerUniversity of Texas, DallasDallas, TXUSAAssistant Professor immunity - Antibiotics resistance
I study antibiotic resistance in, and the in vivo physiology of, pathogenic bacteria. The goals of my research are to: 1) characterize evolutionary and molecular mechanisms contributing to antibiotic resistance in the enterococci and to 2) use in vivo-relevant growth substrates to characterize the physiology of pathogenic bacteria, with each of these goals executed with an eye towards novel antimicrobial development.
AprilPawlukCell PressCambridge, MAUSAEditor interaction
Bacteria and their cognate viruses, known as bacteriophages, are in a constant battle for survival. Among many mechanisms that bacteria possess to defend against bacteriophage infection, one of the most widespread and sophisticated is the CRISPR-Cas system. Setting CRISPR-Cas apart from other defence systems is the fact that it is an adaptive immunity system: one that can acquire the ability to target newly encountered invaders in a sequence-specific manner. Although much has been uncovered about the targeting mechanisms of CRISPR-Cas systems, very little is known about how they select and capture genetic snapshots of bacteriophages for later use as guides for the "seek and destroy" machinery. I leverage biochemical and structural biology approaches to investigate the CRISPR-Cas adaptation process in detail.
Xu PengUniversity of CopenhagenCopenhagenDanmarkGroup leader interaction
Dr. Xu Peng is a group leader in studying Sulfolobus host-virus interactions, viral genomics and structural proteomics.
JenniferPhillipsUniversity of OregonEugene, ORUSAResearch Fellow - Technology development
Our laboratory studies the molecular genetic basis of human diseases, particularly Usher syndrome, the leading cause of combined deafness and blindess, and other diseases of the eye and ear.
VershaPrakashRoyal Holloway, University of LondonLondonUK
Postodoctoal Fellow and social media manager - Gene therapy gene therapy -ataxia telangectasia
Wenning QinBiogen incCambridge, MAUSADirector of Research - Technology development
Wenning has been focusing on and exploring into genetic engineering technologies in her entire professional career. Her association includes Monsanto Biosciences, Pharmacia Corporation, Pfizer Incorporated and the Jackson Laboratory. She currently directs the Genetically Engineered Models group of Biogen, leveraging into genetic engineering to advance drug discovery pipeline for Biogen. Over the years, she acquired extensive knowledge and experience in design and creation of genetically engineered models, using random transgenesis, conventional gene targeting as well as CRISPR/Cas9 technology.
RakhiRajanThe University of OklahomaNorman, OKUSAAssistant Professor biology - Adaptive immunity
Protein-nucleic acid interactions are key to fundamental life processes such as DNA replication, transcription, recombination, and protein synthesis. Deciphering the mechanism of protein-nucleic acid interactions is invaluable for understanding human disease pathways and infections. The primary focus of my lab is to characterize protein-DNA/RNA interactions structurally, biochemically, and biophysically. The immediate emphasis is the study of the recently discovered bacterial and archaeal immune system, CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats). CRISPR is an RNA-based adaptive immune system that inactivates foreign DNA/RNA entering the cell, based on the sequence similarity of small RNAs, called CRISPR RNA (crRNA) to the invading genetic element. The process requires several proteins called CRISPR associated (Cas) proteins. The CRISPR/Cas9 system has revolutionized the genome editing field due to the ease with which targeted double-stranded DNA breaks can be achieved in cells, using a guide RNA and Cas9 protein. The long-term goals of my laboratory are to understand the role of CRISPR/Cas system in pathogenicity and virulence of bacteria, characterize the mechanism of adaptation of bacteria to phage infection, and to determine the signaling mechanisms of the CRISPR/Cas system. We incorporate molecular biology, biochemistry, X-ray crystallography, and additional biophysical tools to characterize these protein-nucleic acid interactions.
MaryClareRollinsMontana State UniversityBozeman, MTUSAResearch Associate
Microbiology - phage bacteria interaction - adaptive immunity
I am fascinated by the biology and ecology of bacteria and their viruses. I want to understand how complex interactions between bacteria and phage have been shaped by billions of years of co-evolution, and how these interactions affect larger ecosystems. I'm currently working on structure/function studies of bacterial adaptive defense systems.
PamelaRonaldUniversity of California - Davis Davis, CAUSAProfessor delivery in crops
Ronald and collaborators lab is working on two projects sponsored by the UC Berkeley Innovative Genomics Institute (hyperlink). We will develop a tissue culture-free CRISPR-Cas9 RNP delivery system for rice. For the second project we will assess public understanding of genome editing
JanetRossantUniversity of Toronto - Sick KidsTorontoCanadaProfessor
Preimplantation - Technology development - mouse transgenesis
We are interested in mechanisms of cell fate decisions in the early mouse embryo and their application to the maintenance and differentiation of embryo-derived stem cells.
DipaliSashitalIowa State UniversityAmes, IAUSAAssistant Professor biology - Adaptive immunity
RNA-protein (RNP) complexes are central to many fundamental processes of gene regulation and genome maintenance in all kingdoms of life. The RNA components of these molecular machines often carry out diverse functions, acting as guide, template, scaffold, or catalyst. Despite this versatility, RNAs require protein partners to function, and the interactions that form between these components often dictate the overall activity of the RNP complex. Our lab is interested in understanding the molecular mechanisms underlying the function of RNPs from diverse cellular pathways. To that end, we combine a broad range of biochemical, structural and cellular tools to study RNA and protein structure, interactions and function.
GeraldineSeydouxJohn Hopkins UniversityBaltimore, MDUSAPrincipal Investigator editing in C.elegrans - Developmental Biology
A major goal of genetic engineering is to develop methods to modify the genome of animals easily and efficiently. CRISPR/Cas9 technology has greatly accelerated progress in this field by providing a simple method to introduce double-strand breaks in the genome. If a DNA with homology to the break (homology arms) is introduced at the same time as Cas9, the cell’s DNA repair machinery will use that DNA to repair the break and copy the sequence between the homology arms into the genome (homology-dependent repair - HDR).Our lab has found that, in C. elegans, homology-dependent repair is remarkably efficient (~100% of breaks repaired by HDR) provided that the repair templates are LINEAR and have short (~35 bases) homology arms that directly flank the Cas9 cleavage site (Paix et al., 2014, 2015).Linear DNAs (ssODNs and PCR amplicons) with 35-base homology arms are sufficient to introduce base- and gene-sized edits (up to 1.6kb).On the basis of these findings, we have developed a cloning-free protocol for editing the C. elegans genome. Our protocol does not require selection markers and uses the same experimental approach to mutate, tag, or delete any gene in the genome.
Lotta-RiinaSundbergUniversity of JyväskyläJyväskyläFinlandGroup leader
Microbiology - phage bacteria interaction - adaptive immunity
In our studies we mainly use the fish pathogen Flavobacterium columnare and its viruses, phages, as a model system. We also work with other phage-bacterium systems originating from the aquatic environment to understand the diversity and evolutionary origins of bacterial viruses.
RebeccaShapiroUniversity of GuelphGuelfCanadaAssistant Professor
Microbiology - fungal genetics - technology development
We are interested in studying microbial fungal pathogens, and we are developing and employing CRISPR-based genomic technologies to allow us to better understand the biology and pathogenesis of these organisms.
NikkiShariatGettysburg CollegeGettysburg, PAUSAAssistant Professor biology - Adaptive immunity
The Shariat Lab research interests are in prokaryote small RNA regulation and function, specifically in Clustered Regularly Interspaced Short Palindromic Repeats (CRISPRs). These elements are present in nearly half of all sequenced bacterial genomes and comprise several unique short sequences, called spacers, which are interspaced by conserved direct repeats. Spacers are derived from exogenous nucleic acids, such as bacteriophage genomes and plasmids. The spacers are transcribed into CRISPR RNAs (crRNAs), which are subsequently targeted to complementary nucleic acids, resulting in degradation of the target. Due to acquisition of new spacers, CRISPRs provide a remarkably dynamic adaptive immune system in both bacteria and archaea.
BettinaSchmidDeutsches Zentrum fur Neurodegenerative ErkankungenHelmotzGermanyHead of laboratory - Technology development
Our group uses the advantages of the zebrafish, Danio rerio, as an in vivo model system to address some of the unresolved questions in Alzheimer’s disease, Parkinson’s disease, Frontotemporal Lobar Degeneration (FTLD), and Amyotrophic lateral Sclerosis (ALS).
KimberleySeedUniversity of California BerkeleyBerkeley, CAUSAAssistant Professor interaction
The ability of V. cholerae to prevent phage predation is critical for its evolutionary fitness and epidemic potential. In turn, as obligate bacterial parasites, phages must co-evolve to overcome this resistance or they will face extinction. Our research is aimed at understanding the bacterial immunity and opposing phage immune evasion strategies at play in this dynamic co-evolutionary arms race. We use comparative genomics and complementary molecular approaches to identify and experimentally validate such strategies in disease associated phage and V. cholerae isolates.
KayleneSimpsonPeter McCallum Cancer CentreMelbourneAustraliaAssociate Professor
High Throughput Screening - Technology Development
The Victorian Centre for Functional Genomics (VCFG) at Peter Mac offers biomedical researchers Australia-wide the ability to perform novel discovery-based functional interrogation all genes in the genome, or selected boutique collections using multiple platforms including CRISPR/cas9, small interfering RNA (siRNA), micro RNA (miRNA) and long non-coding RNA (lncRNA) and short hairpin RNA (shRNA).
LydiaTeboulMRC HarwellLondonUKGroup Leader and Head of Transgenesis Facility development - mouse transgenesis
Dr Lydia Teboul is the Head of Molecular and Cellular Biology at the Mary Lyon Centre at MRC Harwell. Her responsibilities include managing services for genome engineering, expression analysis and embryo phenotyping, as well as providing an advisory role to other teams requiring expertise in molecular biology.
PoojaTiwariGeorgia Institute of TechnologyAtlanta, GAUSAPostdoctoral fellow biology - virology - Technology development
Research in the Santangelo lab is primarily focused on three areas, native RNA regulation, RNA virus pathogenesis, and RNA therapeutics and vaccines, where the application and development of imaging technology is applied to all three areas.
JoyceVan EyckCornell UniveristyIthaca, NYUSAAssistant Professor Biology (Tomato) - Technology Development
The focus of research in the Van Eck laboratory is biotechnological approaches to the study of gene function and crop improvement. For our studies, we apply several genetic engineering strategies to two major food crops: potato and tomato. The development of biotechnological techniques has made it possible to design and introduce gene constructs into plant cells and recover plants that express the introduced genes. Genes of interest to us have the potential to strengthen a plant’s resistance to disease, improve fruit characteristics, and enhance nutritional quality.
AlisonVan EenennaamUniversity of California - DavisDavis, CAUSAGroup leader Genomics and Biotechnology
The mission of the Animal Genomics and Biotechnology Program is to provide research and education on the use of animal genomics and biotechnology in livestock production systems. The research focus of Dr. Alison Van Eenennaam's laboratory is the use of DNA-based biotechnologies in beef cattle production and agricultural systems
StinekeVan HouteUniversity of ExeterExeterUKResearch Fellow interaction
I am a biologist with a broad interest in host-parasite interactions, from an evolutionary, ecological and molecular perspective. Currently I work as a Marie-Curie fellow in the lab of Professor Angus Buckling on the evolution of immunity against virus infections in Pseudomonas bacteria. My PhD research at the Laboratory of Virology, Wageningen University (the Netherlands) focused on manipulation of host insect behaviour by baculoviruses, insect-specific viruses that cause lethal disease in caterpillars.
LeslieVosshallThe Rockfeller UniveristyNew York, NYUSAHead of laboratory - Technology development
The overall goal of work in our laboratory is to understand how complex behaviors are modulated by external chemosensory cues and internal physiological states. The lab takes a multi-disciplinary approach spanning cell biology, genetics, neurobiology and behavior. Our early focus has been to study how the brain interprets olfactory signals in the environment that signal food, danger, or potential mating partners. We have been studying these problems in three model organisms: the fly, the mosquito and the human. The majority of the early work in the laboratory was carried out in the genetically tractable vinegar fly, Drosophila melanogaster, which displays a rich repertoire of chemosensory behaviors despite having a nervous system with only 100,000 neurons. In this animal, we have studied the functional neuroanatomy of the olfactory system, how this system perceives sex pheromones, and the structure and function of the insect odorant receptors.
KanWangIowa State UniversityAgron,IAUSAProfessor biology (Maize) - Technology development
As the rapid development in plant genomics research identifies more genes, their functional analysis relies on strategies such as complementation, overexpression, or gene silencing. Plant genetic transformation is a critical technology required in the application of these strategies.
Rachel WhitakerUniversity of Illinois at Urbana ChampaignUrbana, ILUSAAssociate Professor and Ecology - Adaptive immunity
My lab combines population genomics with laboratory-based genetic and genomic experimental techniques to study the evolutionary ecology of microbial populations. We take a comparative approach, examining interactions within and between species using wild strains from natural populations isolated across spatial and temporal scales. Currently we are working on two critical forces that define the evolutionary process in all organisms: host-virus co-evolution and recombinational gene flow. We have a particular interest in how the unique biology of organisms in the Archaeal domain is reflected in genome architecture and how the CRISPR-Cas immune system functions in microbial populations.
BeekeWienertUniversity of California - BerkeleyBerkeley, CAUSAPostdoctoral fellow
Hematopoiesis - hemoglobin disorders - technology development
Beeke received her PhD in Molecular Genetics and Biochemistry from UNSW Sydney in 2016 and then continued to work as a postdoctoral researcher investigating molecular mechanisms of hemoglobin disorders with Merlin Crossley. In August 2017, she joined the IGI as a postdoctoral researcher. Her main research interests are transcription factors, their binding profiles and how genomic variation causes disease and she is currently using CRISPR/Cas9 to study transcriptional programs of red blood cell enucleation.
SusanWoodsUniversity of AdelaideAdelaideAustraliaSenior Research Fellow biology - Technology Development
Susan’s current project focuses on colorectal cancer. This is the second most common cancer type in Australia, costing us over $1 billion dollars annually. There are minimal effective treatments for advanced disease. The lab has recently identified a new stem cell that gives rise to a layer of cells that support the intestinal lining. We are investigating whether similar support cells can promote the formation of colorectal cancer from cells lining the intestine, and if we can prevent it using a new therapeutic approach.
VanessaYanezTufts UniversityBoston MAUSAPhD student therapy - Age related macular degeneration
Age-related macular degeneration (AMD) is an irreversible destruction of the central area of the retina, called the macula. As many as 11 million Americans have some form of macular degeneration and it is a leading cause of vision loss and irreversible blindness in Americans aged 60 and older. The Kumar-Singh lab has developed a non-viral delivery system that could be used to deliver therapeutics for AMD and Retinitis Pigmentosa effectively. My project focuses on using this system with a cell penetrating peptide called POD to deliver an anti-apoptotic protein to retinal cells to offer protection against retinal degeneration. I will be measuring efficiency of the protein delivery and its function.